A multicentre study was conducted to evaluate the effect of the α-glucosidase inhibitor, voglibose, on glycaemic control in 113 patients with type 2 diabetes whose blood glucose control was poor on treatment with a sulphonylurea drug. The patients were treated for 24 weeks with 0.6 mg voglibose, given orally three times daily, before a meal, together with their usual sulphonylurea drug treatment. In the 86 patients who completed the study, fasting plasma glucose, 2-h post-prandial plasma glucose and haemoglobin showed statistically significant decreases in FPG, 2h-PPG and HbA1c compared with the baseline (P < 0.05) at almost all time-points during treatment. No serious adverse reactions were reported and there were no significant changes in mean body weights. Plasma glucose control was considered to be improved in 65% of patients; there were no adverse events in 92.9% of patients. The results suggest that the combined use of this α-glucosidase inhibitor and sulphonylurea drugs may be effective in controlling plasma glucose in patients with type 2 diabetes and that this combination might delay the onset of vascular complications in these patients.
ZatzRBrennerBMPathogenesis of diabetic microangiopathy: the hemodynamic view. Am J Med1986; 80: 443–453.
2.
BrachBBBlackardWRothschildHA review of deaths due to suspended lactic acidosis at a large metropolitan hospital. South Med J1975; 68: 202–205.
3.
The Physician's Guide to Type II Diabetes (NIDDM): Management of Type II Diabetes Mellitus (RifkinH ed). New York: American Diabetes Association, 1984; 20–52.
UngerRHGrundySHyperglycemia as an inducer as well a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia1985; 28: 19–121.
7.
GrodskyGMPancreatic action of the sulfonylureas. FASEB J1977; 36: 2714–2719.
8.
RiddleMCHartJSBoumaDEfficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetics. Diabetes Care1989; 12: 623–629.
9.
ClarkeBFDuncanLJPComparison of chlorpropamide and metformin treatment on weight and blood glucose response of uncontrolled obese diabetics. Lancet1968; 1: 123–126.
GrayGMCarbohydrate digestion and absorption: role of the small intestine. N Engl J Med1975; 292: 1225–1230.
12.
KamedaYAsanoNYoshikawaMValiolamine, a new α-glucosidase inhibiting aminocyclitol produced byStreptomyces hygroscipius. J Antibiot (Tokyo)1984; 37: 1301–1307.
13.
HoriiSFukaseHMatsuoTSynthesis and α-D-glucosidase inhibitory activity of N-substituted valiomine derivatives as potential oral antidiabetic agents. J Med Chem1986; 29: 1038–1046
14.
MatsuoTOkadaHIdedaHEffect of an intestinal disaccharidase inhibitor (AO)-128), on obesity and diabetes. Am J Clin Nutr1992; 55 (suppl 1): 314–317.
15.
OkadaHMikiNIkedaHEffect of disaccharidase inhibitor, AO-128, on postprandial hyperglycemia on rats. J Jpn Soc Nutr Food Sci1992; 45: 27–31.
16.
GotoYBabaSNakagawaSUtility of an α-glucosidase inhibitor, AO-128, in NIDDM-Phase III double-blind test. Jpn Advance in Medicine (Igaku no Ayumi)1992; 160: 943–971.
17.
KiuraKUmedaFNawadaAClinical utility of AO-128 long-term medication for non-insulin dependent diabetes mellitus (72 cases); Report 2. Jpn Clin Exp Med 1992; 69: 919–932.
18.
KoizumiJMabuchiHTakedoshiTEffects of oral hypoglycemic agents in combination controlled non-insulin dependent diabetes mellitus on AO-128. New Reined Clin1992; 29: 241–252.
19.
UmedaFMimuraKNawadaAEffects of sulfonylureas long-term medication in combination controlled non-insulin dependent diabetes mellitus (NIDDM) on AD-128 (α-glucosidase inhibitor). Jpn J Clin Exp Med1992; 69: 1309–1322.
20.
KawamoriRMorishimaTShibaYThe effectiveness of a new disaccharidase inhibitor AO-128 in glycemic control of insulin-treated diabetic patients. J Jpn Diab Soc1992; 35: 633–640.
MatsuokaATakeuchiKMakimuraHEfficacy and safety of AO-128 long-term treated in non-insulin dependent diabetes mellitus. Med Consult New Remed1992; 29: 255–265.
23.
KamiyaFHayashiYTakeuchiTClinical utility of AO-128 long-term treatment in non-insulin dependent diabetes mellitus. J Adult Dis1992; 22: 573–591.
24.
KohnoSImamuraKKojiSEffects of α-glucosidase inhibitor on insulin sensitivity and decreased level of postprandial plasma glucose in NIDDM patients: evaluation by glucose clamp method (Part 1). Jpn J Clin Exp Med1997; 74: 952–954.
25.
NaoKYmazakiYKatsuraKGlycemic threshold for prevention of diabetic retinopathy: a retrospective study of diabetic outpatients. J Jpn Diab Soc1989; 32: 307–312.
26.
KawaharaRNakagamiT Clinical study of treatments on diabetes mellitus: clinical factors for prevention of diabetic retinopathy. The Ministry of Health and Welfare, 1993; 267–269.
27.
UmenoYLimoriKEndoMCombination effects of voglibose and sulfonylureas in non-insulin dependent diabetes mellitus (NIDDM) patients. Jpn Clin Exp Med1997; 74: 739–744.
28.
IijimaTMakinoTTakahashiHUsefulness of combination therapy with sulfonylurea and α-glucosidase inhibitor (voglibose) in non-insulin dependent diabetes mellitus: effect of reducing the dose of sulfonylurea. Jpn Pharmacol Ther1997; 25: 841–849.
29.
KandaTImanoHMatsushimaHUsefulness of combination therapy with preprandial rapid-acting insulin injection and α-glucosidase inhibitor in non-obese NIDDM patients with secondary failure on oral hypoglycemic agents. J Jpn Diab Soc1996; 39: 183–190.
30.
OdakaHMikiNIkedaHEffect of intestinal disaccharidase inhibitor, AO-128, on carbohydrate, protein, fat, and vitamin absorption in rats. Jpn Pharmacol Ther1991; 19: 4439–4450.
31.
IkedaHOdakaHMatsuoTAntiobesity and antidiabetic action of a disaccharidase inhibitor, AO-128, in genetically obese-diabetic mice, KKAy. J Nutr Sci Vitaminol (Tokyo)1991: 19: 4105–4117.
32.
MatsuoTOdakaHIkedaHEffect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am J Clin Nutr1992; 55 (suppl 1.1): 314–317.
33.
ShimuraYOdakaHIkedaH Obesity suppression and anti-diabetic activity on AO-128. Proceedings of the 7th Congress of Japan Aged Society Supporting Organization 1986; 210–211.
34.
InuiYKawataSMatsuzawaYInhibitory effect of a new α-glucosidase inhibitor on fatty liver in zucker fatty rats. J Hepatol1990; 10: 62–68.
35.
InuiYKawataSKohataRThe effects of an α-glucosidase inhibitor on fatty liver in obesity. Jpn J Gastroenterol1987; 84: 1639–1644.
36.
Report of the Expert Committee on the diagnosis and the classification of diabetes mellitus. Diabetes Care1997; 20: 1183–1197
